Calycosin inhibits the proliferation and metastasis of renal cell carcinoma through the MAZ / HAS2 signaling pathway
Phytotherapy Research · 2024-09 · 38 (9) · 4774-4791
DOI: 10.1002/ptr.8295 ↗At a glance
Journal article in Phytotherapy Research, published online on 2024-08-09. Written by Zi-Hao Zhang and 11 co-authors. Institution: Department of Urology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China. Major MEDLINE topics: Carcinoma, Renal Cell, Cell Proliferation, Isoflavones, Kidney Neoplasms. Cited 11 times so far (Crossref); 46 references. Funded by: National Natural Science Foundation of China.
Abstract (original language)
Calycosin (Caly), a flavonoid compound, demonstrates a variety of beneficial properties. However, the specific mechanisms behind Caly's anticancer effects remain largely unexplored. Network pharmacology was used to explore the potential targets of Caly in renal cancer. Additionally, RNA‐seq sequencing was used to detect changes in genes in renal cancer cells after Caly treatment. Validation was carried out through quantitative reverse transcription‐PCR and Western blot analysis. The luciferase reporter assay was applied to pinpoint the interaction site between MAZ and HAS2. Furthermore, the immunoprecipitation assay was utilized to examine the ubiquitination and degradation of MAZ. In vivo experiments using cell line‐derived xenograft mouse models were performed to assess Calycosin's impact on cancer growth. Network pharmacology research suggests Caly plays a role in promoting apoptosis and inhibiting cell adhesion in renal cancer. In vitro, Caly has been observed to suppress proliferation, colony formation, and metastasis of renal cancer cells while also triggering apoptosis. Additionally, it appears to diminish hyaluronic acid synthesis by downregulating HAS2 expression. MAZ is identified as a transcriptional regulator of HAS2 expression. Calycosin further facilitates the degradation of MAZ via the ubiquitin‐proteasome pathway. Notably, Caly demonstrates efficacy in reducing the growth of renal cell carcinoma xenograft tumors in vivo. Our findings indicate that Caly suppresses the proliferation, metastasis, and progression of renal cell carcinoma through its action on the MAZ/HAS2 signaling pathway. Thus, Caly represents a promising therapeutic candidate for the treatment of renal cell carcinoma.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Urology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
- Shanghai Genitourinary Cancer Institute, Shanghai, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Department of Urology, School of Life Medicine, Fudan University Shanghai Cancer Center, Qingdao Institute, Fudan University, Qingdao, China.
- Central Laboratory, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
ORCID profiles: Zi-Hao Zhang
Funding
- National Natural Science Foundation of China
Cite
APA
Zhang, Z. H., Yuan, C. Y., Xu, M., Wang, M. F., Feng, T., Wang, Y., Zheng, S. F., Zhang, H. L., Shi, G. H., Cao, D. L., Wang, Z. L., & Ye, D. W. (2024). Calycosin inhibits the proliferation and metastasis of renal cell carcinoma through the MAZ / HAS2 signaling pathway. Phytotherapy Research, 38(9), 4774-4791. https://doi.org/10.1002/ptr.8295
Vancouver
Zhang ZH, Yuan CY, Xu M, Wang MF, Feng T, Wang Y, et al. Calycosin inhibits the proliferation and metastasis of renal cell carcinoma through the MAZ / HAS2 signaling pathway. Phytotherapy Research. 2024;38(9):4774-4791. doi:10.1002/ptr.8295
BibTeX
@article{Zhang2024,
author = {Zhang, Zi-Hao and Yuan, Cheng-Yue and Xu, Meng and Wang, Meng-Fei and Feng, Tao and Wang, Yue and Zheng, Sheng-Feng and Zhang, Hai-Liang and Shi, Guo-Hai and Cao, Da-Long and Wang, Zi-Liang and Ye, Ding-Wei},
title = {Calycosin inhibits the proliferation and metastasis of renal cell carcinoma through the MAZ / HAS2 signaling pathway},
journal = {Phytotherapy Research},
year = {2024},
volume = {38},
number = {9},
pages = {4774--4791},
doi = {10.1002/ptr.8295}
}
EUVIMED